Susquehanna International Group
CNTA

Susquehanna International Group’s Centessa Pharmaceuticals CNTA Stock Holding History

Susquehanna International Group’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.72M Sell
118,800
-41,700
-26% -$1.07M ﹤0.01% 4336
2025
Q4 		$4.01M Sell
160,500
-269,800
-63% -$6.83M ﹤0.01% 4376
2025
Q3 		$10.4M Buy
430,300
+238,200
+124% +$4.23M ﹤0.01% 2988
2025
Q2 		$2.52M Buy
192,100
+112,800
+142% +$1.43M ﹤0.01% 5307
2025
Q1 		$1.14M Buy
+79,300
New +$1.3M ﹤0.01% 6920
2024
Q1 		– Sell
-11,200
Closed -$89.2K – 12306
2023
Q4 		$89.2K Sell
11,200
-7,300
-39% -$48.9K ﹤0.01% 11411
2023
Q3 		$120K Buy
+18,500
New +$127K ﹤0.01% 10774

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Susquehanna International Group's CNTA Position: Q1 2026 in Review

Susquehanna International Group increased its Centessa Pharmaceuticals (CNTA) stake by 53% in Q1 2026, buying an estimated $158K and bringing the position to 17,737 shares worth $705K. The position accounts for ﹤0.01% of the portfolio, ranked #8799.

Susquehanna International Group first reported a position in CNTA in Q1 2023 and has held it in 6 quarters since. The position peaked at $12.9M in Q1 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Susquehanna International Group held 17,737 shares of Centessa Pharmaceuticals worth $705K as of Q1 2026.
  • Susquehanna International Group bought 6,174 Centessa Pharmaceuticals shares in Q1 2026, an estimated $158K.
  • Centessa Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8799 holding.
  • Susquehanna International Group first reported a position in Centessa Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
  • Susquehanna International Group's Centessa Pharmaceuticals position peaked at $12.9M in Q1 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.